| (Values in U.S. Thousands) | Jun, 2021 | Mar, 2021 | Dec, 2020 | Sep, 2020 | Jun, 2020 |
| Sales | 3,360 | 470 | 1,500 | 1,110 | 1,340 |
| Sales Growth | +614.89% | -68.67% | +35.14% | -17.16% | -51.27% |
| Net Income | -17,110 | -30,680 | -15,640 | -13,460 | -13,280 |
| Net Income Growth | +44.23% | -96.16% | -16.20% | -1.36% | +37.12% |
Cerecor Inc (CERC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cerecor, Inc. is a biopharmaceutical company which focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company's portfolio of clinical and preclinical candidates consists of CERC-301, CERC-501 and CERC-406. CERC-301; adjunctive antidepressant for the treatment of patients with major depressive disorder; CERC-501, for co-occurring psychiatric and substance use disorders and CERC-406, for the treatment of residual cognitive impairment symptoms. Cerecor, Inc. is headquartered in Baltimore, Maryland.